Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VesiculoVax HIV gag vaccine
- Development stage
- Unknown
- Lead developer
- Aurobindo Pharma
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VesiculoVax HIV gag vaccine is an investigational viral vector vaccine developed by Auro Vaccines for the prevention and treatment of HIV infection. The vaccine utilizes a proprietary, highly attenuated, and replication-competent recombinant vesicular stomatitis virus (rVSV) vector to express the HIV-1 gag antigen. It is a key component of the PBS Vax™ prime/boost platform, where it typically serves as a boost following a GeneVax™ DNA vaccine prime to induce robust cellular (CD4+ and CD8+ T cell) and humoral immune responses. The vaccine has been evaluated in Phase 1 clinical trials, including HVTN 090 and HVTN 087, demonstrating safety, tolerability, and immunogenicity in healthy volunteers and HIV-infected individuals. The technology was originally developed by Profectus BioSciences before being acquired by Auro Vaccines.
- Brand names
- VesiculoVax
- Other names
- rVSV HIV-1 gag vaccineVSV-Gag vaccineHVTN Trial 090 vaccine
02
Targets
Gag (HIV-1 Gag polyprotein)
Beyond the preview
Go deeper on VesiculoVax HIV gag vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VesiculoVax HIV gag vaccine.